Earnings summaries and quarterly performance for ImageneBio.
Research analysts covering ImageneBio.
Recent press releases and 8-K filings for IMA.
ImageneBio Updates Corporate Presentation, Highlights IMG-007 Progress
IMA
New Projects/Investments
Guidance Update
- ImageneBio, Inc. (IMA) updated its corporate presentation on November 19, 2025, for use with investors and analysts, highlighting its lead product, IMG-007.
- The company, which became public in July 2025, is well-funded with a cash runway expected through the end of 2027.
- IMG-007 demonstrated rapid and notable improvement in a Phase 1b/2a study for moderate-to-severe atopic dermatitis (AD), achieving an 87% mean reduction in EASI score from baseline at week 20, alongside a favorable safety profile.
- The Phase 2b ADAPTIVE trial for IMG-007 in AD is currently recruiting, with topline data expected in 2027.
- IMG-007 also showed proof-of-concept and was well tolerated in a Phase 1b/2a study for alopecia areata (AA), indicating its potential across multiple autoimmune and inflammatory diseases.
Nov 19, 2025, 12:50 PM
ImageneBio Reports Q3 2025 Financial Results and Program Updates
IMA
Earnings
Management Change
New Projects/Investments
- ImageneBio reported $142.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, following a reverse merger and a $75.0 million private placement.
- For the three months ended September 30, 2025, the company recorded a net loss of $24.8 million, an increase from $3.2 million in the prior year period, primarily due to merger-related operating and transaction costs.
- ImageneBio plans a protocol amendment for its Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis to optimize study design, with topline data anticipated in 2027.
- The company will present new clinical data for IMG-007 in alopecia areata and atopic dermatitis at the Inflammatory Skin Disease Summit from November 12-15, 2025.
- The leadership team was strengthened with Dr. Kristin Yarema appointed as CEO, along with new Chief Strategy and Operations Officer, Chief Technical Officer, and an independent director to the Board.
Nov 12, 2025, 12:25 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more